



February 17, 2006

## **Peregrine Pharmaceuticals to Present at Roth Capital Partners 18th Annual OC Conference**

TUSTIN, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that Peregrine CEO and president Steven W. King will present at the Roth Capital Partners 18th Annual OC Conference on Tuesday, February 21 at 1:30pm PST. The conference will be held at the St. Regis Resort, Dana Point, CA, February 20-22, 2006.

For more information on the conference, please visit <http://www.rothcp.com/index06 DP.html>

### About Peregrine

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin™ and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [www.peregrineinc.com](http://www.peregrineinc.com).

SOURCE Peregrine Pharmaceuticals, Inc.

CONTACT: Investors, Brod & Schaffer, +1-800-987-8256, [ir@peregrineinc.com](mailto:ir@peregrineinc.com), for Peregrine Pharmaceuticals, Inc.; or Media, Barbara Lindheim of GendeLLindheim BioCom Partners, +1-212-918-4650, for Peregrine Pharmaceuticals, Inc.